$6.8 Bn Glaucoma 68-Market Analysis and Sales Forecasts 2023-2033 Featuring Abbvie, Allergan, Alcon, Pfizer, Merck, Santen, Ocular Therapeutix, pH Pharma, Nicox, DWTI, Thea Pharma, Betaliq, and Tarsier Pharma
17. Januar 2025 06:23 ET
|
Research and Markets
Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Glaucoma: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68 geographical...
Iantrek Announces First Commercial Cases of its C.Rex Micro-Interventional System for Trabecular Outflow Enhancement
13. Januar 2025 08:00 ET
|
Iantrek, Inc.
White Plains, NY., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc, a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional technologies for the...
Iantrek Announces Peer-Reviewed Publication Highlighting 12-Month Safety and Effectiveness Results for its Bio-Interventional Uveoscleral Outflow Technology in Open-Angle Glaucoma Patients
10. Dezember 2024 08:00 ET
|
Iantrek, Inc.
White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and...
Glaucoma Therapeutics Strategic Industry Report 2024 - Growth in Specialty Eye Clinics Enhancing Treatment Reach
09. Dezember 2024 11:03 ET
|
Research and Markets
Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Glaucoma...
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
19. November 2024 08:00 ET
|
SpyGlass Pharma, Inc.
SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...
SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
17. Oktober 2024 14:35 ET
|
SpyGlass Pharma, Inc.
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
13. September 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
10. September 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs
04. September 2024 07:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR...
Global Next Generation Contact Lenses & Visual Prostheses Market to Reach USD 715.57 Million by 2030
12. August 2024 04:12 ET
|
Research and Markets
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "Global Next Generation Contact Lenses & Visual Prostheses Market by Product (Diagnostic or monitoring contact lenses, Drug-eluting contact lenses,...